Grossman Jerrold B 4

What Happened
Jerrold B. Grossman, a director of ADMA BioLogics (ADMA), was granted equity awards on February 9, 2026: 10,690 restricted stock units (RSUs) and an additional 17,730 reported as derivative awards. Both grants were recorded at $0.00 per share (award/compensation, transaction code A), so no cash changed hands. These are awards (not open‑market purchases or sales) and are typical form of director compensation rather than a direct investment signal.

Key Details

• Transaction date: February 9, 2026; Form 4 filed February 11, 2026 (timely filing).
• Awards: 10,690 RSUs (award at $0.00) plus 17,730 derivative award units (award at $0.00).
• Vesting: The RSUs vest in two equal installments (six- and 12‑month anniversaries) and will be fully vested on the one‑year anniversary, per the filing (the 10,690 RSUs are noted to fully vest by Feb 9, 2027, subject to continued service).
• Holdings reported (per footnote F2): the reporting person beneficially owns 472,749 common shares and has unvested RSUs including the 10,690 granted Feb 9, 2026 and 5,445 remaining RSUs from a Feb 19, 2025 grant (the 5,445 are scheduled to vest Feb 19, 2026).
• Ownership through entities (per footnotes): some shares are held via Brookwood LLC (Grossman is managing member), the Jerrold Grossman 2019 Irrevocable Trust (he is investment trustee), Genesis Foundation Inc. (he is President), and shares owned by his wife.
• Transaction type: A = Award/Grant (not a purchase, sale, exercise, or gift). No tax‑withholding sale or cashless exercise was reported.

Context
RSU awards are standard compensation for directors and vest over time subject to continued service; they do not represent an immediate sale or purchase of stock. For retail investors, grants are informative about company compensation practices but do not by themselves indicate that insiders are buying (bullish) or selling (bearish).